Medical Marijuana, Inc. holds the distinction of being the first publicly listed marijuana stock, and its diversity is rare, but is it worth investing in?
Tag Archives: GW Pharmaceuticals
The threat of increasing competition for GW Pharmaceuticals’ promising epilepsy drug took a toll on investors’ confidence last month.
In the red-hot world of marijuana stocks, there can be no question that GW Pharmaceuticals reigns supreme, but could small-cap biotech Zogenix be a threat?
If there is a “Holy Grail” milestone out there for cannabis stocks, it’s the $1 billion sales mark. The first cannabis company to hit $1 billion in sales will likely validate the industry to Wall Street and investors. But which marijuana stock has the best chance at being first to $1 billion in annual sales?
GW Pharmaceuticals is set to file its cannabis-derived drug with U.S. regulators imminently, following publication of detailed data on its success in fighting severe childhood epilepsy.
Here’s why these three cannabis stocks are in better shape than most others in the market. Take a deeper look into GW Pharmaceuticals, Insys Therapeutics, and Aphria.
The marijuana industry, and marijuana stock investors for that matter, have been expanding by leaps and bounds over the past two decades. One good way to keep this up is through university-based clinical studies. Studies like these really fan the flame of what might be possible with cannabis-based medicines.
The recently debuted marijuana stock ETF, the Horizons Medical Marijuana Life Sciences ETF, has lost value for those who’ve decided to take the plunge.
A major Canadian medical marijuana player, Canopy Growth is a producer and retailer of medical cannabis products and oils in our neighbor to the north. It’s also the only other marijuana stock other than GW Pharmaceuticals to bear a $1 billion valuation.
The marijuana industry is the hottest thing since sliced bread, and marijuana stocks are thriving. Here’s a quick rundown of the largest players.
Can marijuana stocks keep going higher? The answer could depend more on the laws of supply and demand than current U.S. laws.
With two marijuana stocks already sporting market caps over $1 billion, one of these four pot stocks is likely to be next.
Here are 4 top stocks in the growing medical marijuana industry that have a tremendous amount of potential for investors.
LONDON, April 18, 2017 /Weed Wire/ – GW Pharmaceuticals noted that the American Academy of Neurology (AAN) issued a press release today announcing positive results from a second Phase 3 study (GWPCARE3) of Epidiolex.
These 5 marijuana stocks lost a combined $193 Million in 2016. Though they’re some of the top performers, they’re also among the companies losing the most money on an annual basis.
Medical marijuana remains the safest investment route — if you’re forced to choose one — so here’s a brief rundown of the cannabinoid-based drugs working their way through clinical and preclinical trials.
Although marijuana stocks have skyrocketed in the last couple of years, many investors have been understandably leery of jumping on board. Check out why investors might like these three stocks that don’t fit the mold of most marijuana stocks.
LONDON, March 29, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product Epidiolex®.
Israel, a leader in marijuana research and health technology, is attracting international investment as it tries to position itself as a cutting-edge exporter in the rapidly-growing market for medical-grade cannabis.
Legal marijuana flat-Earthers, like U.S. Attorney General Jeff Sessions, have tried many methods to discredit breakthroughs in medical cannabis, but these efforts at discrediting cannabis stop at the U.S. border.
Insys Therapeutics announced a compassionate-use program for its cannabis-based epilepsy drug, igniting optimism that the company is continuing to develop marijuana medicine.
SAN DIEGO, Calif., March 3, 2017/Weed Wire/ — Mentor Capital, Inc. (OTCQB: MNTR) announced it has taken a $1.0 million position in the stock of GW Pharmaceuticals, Plc (NASDAQ: GWPH), a United Kingdom based group developing a portfolio of cannabinoid prescription medicines.
A federal crackdown on marijuana isn’t bad news for all marijuana stocks.
Over the next five years, the U.S. marijuana market could be worth tens of billions of dollars, and according to GreenWave Advisors, LLC, these five states could move the needle most for marijuana companies. Learn just how big the marijuana market may be in California, Washington, Pennsylvania, Colorado, and Michigan in 2021.
The cannabis industry is expected to reach $50 billion in size by 2026, according to Cowen & Co., making it one of the fastest growing industries in the world. Investors have taken a growing interest in the industry as legalization has spread across North America. Here are three subsets of the cannabis industry that investors may want to consider for the best risk-adjusted returns.
Marijuana stocks are riding high as the stock index is up for the eighth consecutive week.
The company announced Tuesday positive top-line results from a mid-stage placebo-controlled study of a proprietary combination of tetrahydrocannabinol, or THC, and cannabidiol, or CBD, for treating glioblastoma multiforme, or GBM.
LONDON, Feb. 7, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study.
Marijuana prices are falling. Could marijuana stock prices drop soon, too?
Florida is undeniably behind the curve when it comes to passing pro-pot legislation, but the Sunshine State did make up some ground in November, when voters legalized medical marijuana in the state. How big could the medical marijuana market be in Florida for marijuana stocks?
Forward-thinking investors are already plotting seven-figure weed windfalls with the top pot stocks from every ecosystem. You see, there’s more to the marijuana industry than just selling cannabis. There are a lot of ways to profit from legal recreational and medical marijuana sales.
“Cannabis in Parkinson’s Disease: Growing Like a Weed!” was presented at the University of Colorado School of Medicine’s Neurology Grand Rounds on Jan. 18, 2017.
Investing in cannabis stocks is being called the “gold rush” of the 21st century. That’s because legal marijuana sales in North America climbed to $6.7 billion in 2016.
Marijuana stocks may be in for a bumpy ride this year.
The market for marijuana is exploding as Americans overwhelmingly embrace legalization. Analysts are projecting tens of billions of dollars in future marijuana sales, making this an intriguing market for investors.
Marijuana sales has the potential to greatly add to government’s treasury as well, and it will be immensely helpful in medical fields. Nowadays, it is also easier for banks for provide services for legal marijuana businesses.
A comprehensive study slams many of the alleged benefits of marijuana and points to serious negative effects. What will the impact of this study be for marijuana stocks?
Sales in the legal marijuana industry are skyrocketing, which is why Money Morning created a list of the top marijuana stocks to watch in 2017. But because marijuana is still illegal under federal law, and many of the marijuana stocks on the market are so volatile, this isn’t a list of recommendations. Rather, it’s a list of marijuana stocks they are watching closely in 2017.
Most myths have at least a little bit of truth interspersed with a lot that is false. That’s the case with these three myths about marijuana stocks that some might mistakenly believe.
While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant’s cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions.
If you’re considering investing in marijuana stocks in the new year, here are five numbers you should know before taking the plunge.
Let’s take a look back on this past year and see what the future holds for marijuana stocks.
According to a report by the equity research firm Cowen & Co., marijuana will generate $50 billion in revenue by 2026. That’s roughly eight times the estimated revenue this year. GW Pharmaceuticals and Insys Therapeutics are two big companies with an even bigger future.
LONDON, Dec. 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced additional positive Epidiolex® (cannabidiol or CBD) Phase 3 data in poster presentations at the 70th Annual Meeting of the American Epilepsy Society.
On Oct. 2, 2016, Maureen Leehey, MD, discussed the potential of cannabis in treating Parkinson’s disease at the 3rd Annual Parkinson’s Disease Symposium at the University of Colorado Movement Disorders Center.
On Sept. 26, 2016, GW Pharmaceuticals (Nasdaq:GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for its third study in the United States on the efficacy of Epidiolex, its experimental CBD-based drug, in treating seizures associated with Lennox-Gastaut syndrome.
An experimental cannabis-derived drug has successfully treated children with severe epilepsy in a third late-stage clinical trial, sending shares in Britain’s GW Pharmaceuticals to a record high on Monday.
LONDON, Sept. 26, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex.
GW Pharmaceuticals Plc (Nasdaq:GWPH), a developer of marijuana-based epilepsy treatments, is working with an investment bank after other drugmakers approached it to express interest in an acquisition, people familiar with the matter said.
The medical sector of the cannabis industry continues to explode behind constant research and innovative studies for identifying viable cancer treatments and other therapies for different ailments.